What Hims actually launched
On October 21, 2026, Hims & Hers added three testosterone options to its men's health program and called it its "largest men's health launch to date" (Hims & Hers). The three are a compounded testosterone injection given subcutaneously twice a week, generic testosterone cypionate given intramuscularly once a week, and Kyzatrex, a branded oral capsule that is FDA-approved and comes through an exclusive deal with Marius Pharmaceuticals announced in September 2025. They sit next to compounded enclomiphene, which Hims has sold since September 10, 2025.
The care model matters more than the SKUs. Every patient starts with an intake, then an at-home blood collection using a push-button device worn on the upper arm, processed by a CLIA-certified lab for 22 biomarkers including total and free testosterone, SHBG, an advanced lipid panel and glycemic markers. A licensed provider reviews the results in a live visit before anything is prescribed, and follow-up labs are part of the program. The release says the service is not available in every state and the lab test is not available in Hawaii.
What the release does not include: prices. We could not find a published Hims price for any of the three new products as of early November, so we will not guess one here.
Hims reports third-quarter results after the market closes today. Its CFO, Yemi Okupe, has said he expects testosterone to reach a $100 million annual run rate "in the coming quarters" and has described injectable testosterone as one of the company's "higher complexity offerings" (TIKR). If you want one number from tonight's call, listen for whether management sizes TRT at all. The earnings listening guide has the rest of the list.
"We test first" is no longer a moat
In August we told independent TRT founders to be the labs-forward program (How to Start an Online TRT Clinic in 2026). That advice still holds as clinical practice. As positioning, it is weaker than it was a month ago, because the largest brand in the category now requires a lab panel and a live visit too.
Be honest with yourself about what is left. Hims has a national brand, an at-home collection device, a pharmacy operation and the marketing budget to rank for "testosterone therapy online." An independent will not win on convenience, and it should not try to win on price against a company that compounds at scale.
What an independent can still win on is depth: of monitoring, of the clinical relationship, and of fit for patients a national funnel serves badly.
| Area | Hims, per its October 21 release | Where an independent can differ |
|---|---|---|
| Products | Compounded SC injection, generic cypionate IM, Kyzatrex oral (plus enclomiphene since 2025) | Fewer products, chosen and explained by one medical director |
| Labs | At-home device, 22 biomarkers, follow-up labs | Venous draw option, published monitoring schedule, results explained by the same clinician each time |
| Clinician | Licensed provider, live visit at start | A named clinician the patient keeps, with a stated response time |
| Price | Not published in the release | Full monthly price, labs included or listed line by line, on the pricing page |
| Patients | Men, national | A niche: women, a community, an audience you already have |
Four places an independent testosterone brand can still win
Price you can read before you start. A patient comparing TRT options in November sees ads, not prices. Put the whole number on your pricing page: the baseline panel, the monthly program fee, what each follow-up lab costs or that it is included, and what changes if the dose changes. Most patients will not choose you because you are cheapest. Some will choose you because you were the only one who told them.
The same clinician, on purpose. Testosterone therapy is a long relationship with frequent decisions: the 6 to 8 week recheck, hematocrit drifting up, a dose change, a question about fertility. A program where the patient talks to the same clinician, who remembers the last conversation, is something a national queue finds hard to promise. If you offer it, write it down: who the clinician is, how fast they answer, what happens when they are away. Clinical governance as a growth asset is the longer version of this argument.
Patients the big launch does not address. Hims built its launch for men. Women's testosterone is a separate, smaller and clinically different category with its own dosing, its own off-label questions and its own evidence base, and very few DTC brands do it well (our women's testosterone post). The same logic applies to men trying to preserve fertility, older men with cardiovascular history who need closer monitoring, or an audience you already own: a gym chain, a coaching business, a creator with men's health followers. Distribution you have beats distribution you rent from Meta.
Bundles a single-category funnel will not build. Many TRT patients are also on, or asking about, a GLP-1. A program that manages both under one clinician, with one set of labs, has a real reason to exist. The CVS post makes the same case for weight care: when a giant sells the visit cheaply, sell what happens after it.
What we would not do: launch a compounded injection just because Hims did. Compounded testosterone is not FDA-approved, compounding rules differ by state, and the DEA question below hits injectables and orals the same way. Pick formulations your medical director will defend in writing.
Where the DEA rule stands, early November
Testosterone is Schedule III. Prescribing it by telehealth without a prior in-person exam depends on the DEA's temporary flexibilities, which expire December 31, 2026.
As of the first week of November there is no final Special Registration rule and no fifth extension. The final rule has been at the White House Office of Information and Regulatory Affairs since August 25, 2026; OIRA's listing shows a stakeholder meeting completed on October 16 and another scheduled for November 2 (reginfo.gov), and the Justice Department's agenda still points to November for final action.
On November 2, an Alliance for Connected Care coalition letter to DEA Administrator Terrance Cole and OMB Director Russell Vought asked for a fifth temporary extension through at least December 31, 2027, and asked for it soon. The letter notes the fourth extension was published December 30, 2025, a day before the old deadline, and that providers book appointments 30 or more days out (AAHD).
That last-minute pattern is the base case we plan around. We do not know whether December brings a rule, an extension, both (a rule with a delayed effective date), or nothing. Nobody outside OIRA and DEA does.
Seven weeks: what to prepare either way
| Do this by | If a final rule publishes | If an extension publishes, or nothing does |
|---|---|---|
| Now | Read the rule the day it lands; map each clinician to the registration type the final text requires | Keep the contingency plan live; do not stand it down on rumors |
| November 20 | List every active patient whose next prescription falls after December 31, by state | Same list; it is your exposure either way |
| December 1 | Start registration applications for prescribers (and ask your platform what it needs) | Confirm your in-person fallback: local clinics or partner practices for an exam in each state you serve |
| December 15 | Draft patient emails for "nothing changes for you" and "you need a visit before your next refill" | Send the second email to affected patients if no extension has published |
| December 31 | Switch workflows to the rule's conditions on its effective date | If nothing published, stop new telehealth-only starts; existing patients follow your fallback plan |
The scenario detail, including which programs are most exposed, is in the 120-day contingency plan. One point worth repeating: if the final rule keeps the proposal's separate registration for telemedicine platforms, your software vendor's status becomes part of your compliance. Ask now, in writing.
This is not legal advice; a DEA-experienced healthcare attorney should review your plan for each state you serve.
Where Turbopills fits
Turbopills gives a TRT brand the software side: a storefront on your domain, intake that can require labs before checkout and before provider review, state-aware routing to licensed providers, billing that starts only when a provider approves, pharmacy routing, and a patient portal where lab results and symptom check-ins sit together. When the DEA picture changes, routing rules and patient messaging change in configuration, not in a rebuild.
What stays with you: the professional entity, the medical director and the protocol, DEA registrations, your lab and pharmacy choices, and the marketing. We are in private beta and quote per program. In a demo, ask us to show a lab-gated intake and a refill flow for a patient in a state where you have flagged an in-person requirement.
FAQ
Does Hims offer testosterone replacement therapy? Yes. On October 21, 2026 Hims added a compounded twice-weekly subcutaneous injection, generic testosterone cypionate and the oral Kyzatrex to its low-testosterone program, after an at-home lab test and a live provider visit. It is not available in every state, and Hims did not publish prices in its launch release.
Can testosterone be prescribed online after December 31, 2026? It depends on what the DEA does in December. As of early November there is no final Special Registration rule and no fifth extension of the telemedicine flexibilities. If neither arrives, a prior in-person evaluation would be needed for new telehealth testosterone prescriptions.
How can a small TRT clinic compete with Hims? Publish the full price including labs, keep patients with one named clinician, serve patients a national funnel underserves (women, fertility-focused men, an audience you already own), and bundle related care such as GLP-1 treatment under one clinician.
Is compounded testosterone FDA-approved? No. Compounded testosterone is not FDA-approved. Generic testosterone cypionate and Kyzatrex are FDA-approved products.